Clinical Trial

Drug-Drug Interaction Study of ABP-671 in Gout Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 14, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-15
Trial Details
NCT Number NCT07367971
Lead Sponsor Atom Therapeutics Co., Ltd
Conditions Gout Chronic, Gout, DDI (Drug-Drug Interaction)
Enrollment 20 participants
Start Date 2026-01-23
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-14